Drug approval: future aspects of the FDA.
作者信息
Skelly J P
机构信息
University of Cincinnati, Ohio, USA.
出版信息
Methods Find Exp Clin Pharmacol. 1998 Jul-Aug;20(6):527-37. doi: 10.1358/mf.1998.20.6.485716.
PMID:9789876
Abstract
摘要
相似文献
1
Drug approval: future aspects of the FDA.药物审批：美国食品药品监督管理局的未来展望
Methods Find Exp Clin Pharmacol. 1998 Jul-Aug;20(6):527-37. doi: 10.1358/mf.1998.20.6.485716.
2
Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program.加拿大恶性血液病和肿瘤学适应证的监管和卫生技术评估与美国食品和药物管理局加速批准计划的比较。
JAMA Netw Open. 2021 Aug 2;4(8):e2120301. doi: 10.1001/jamanetworkopen.2021.20301.
3
4
Vision and will: the future of the FDA.愿景与意志：美国食品药品监督管理局的未来
Oncologist. 2009 Apr;14(4):317-9. doi: 10.1634/theoncologist.2009-0053. Epub 2009 Apr 13.
5
New FDA breakthrough-drug category--implications for patients.美国食品药品监督管理局新的突破性药物类别——对患者的影响。
N Engl J Med. 2014 Mar 27;370(13):1252-8. doi: 10.1056/NEJMhle1311493.
6
Regulatory watch: FDA guidance on co-developing investigational drugs.监管观察：美国食品药品监督管理局关于共同开发研究性药物的指南
Nat Rev Drug Discov. 2011 Feb;10(2):86. doi: 10.1038/nrd3363.
7
FDA under pressure to relax drug rules.美国食品药品监督管理局面临放宽药品规定的压力。
Nature. 2012 Dec 6;492(7427):19. doi: 10.1038/492019a.
8
Communicating with the FDA: the "third rail" of a new model for drug development.与美国食品药品监督管理局沟通：药物研发新模式的“高压线”
J Clin Pharmacol. 2008 Feb;48(2):144-5. doi: 10.1177/0091270007313560.
9
Patent watch: post-approval testing shielded from patent infringement.专利观察：批准后测试免受专利侵权影响。
Nat Rev Drug Discov. 2012 Sep;11(9):666.
10
Examining Manufacturing Readiness for Breakthrough Drug Development.审视突破性药物研发的生产准备情况。
AAPS PharmSciTech. 2016 Jun;17(3):529-38. doi: 10.1208/s12249-015-0455-1. Epub 2015 Nov 25.
Zotero 插件